p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

Blood
Hong ChangA Keith Stewart

Abstract

We investigated the relevance of p53 deletions to the clinical outcome of patients with multiple myeloma (MM) treated with high-dose chemotherapy and autologous stem cell transplantation. Hemizygous p53 gene deletions were detected by fluorescence in situ hybridization in 10 of 105 (9.5%) patients studied. p53 deletions were associated with higher serum calcium (P = .0062) and creatinine (P = .013) levels, but there were no association with patient age, gender, beta2-microglobulin, C-reactive protein, hemoglobin, albumin or bone lytic lesions, or immunoglobulin isotype. There were no associations of p53 deletions with 13q deletions or translocations t(11;14) or t(4;14). Patients with p53 deletions had significantly shorter progression-free (median, 7.9 versus 25.7 months, P = .0324) and overall survival (median, 14.7 versus 48.1 months, P = .0008) than patients without a p53 deletion. A multivariate analysis confirmed p53 deletion was an independent prognostic factor predicting shortened progression-free (P = .0009) or overall survival (P = .0002) in patients with MM after high-dose chemotherapy and autologous stem cell transplantation.

References

Jul 1, 1992·British Journal of Haematology·C PreudhommeP Fenaux
Oct 14, 1995·Lancet·D A Carson, A Lois
Sep 1, 1999·British Journal of Haematology·H Avet-LoiseauR Bataille
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KönigsbergJ Drach
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party

❮ Previous
Next ❯

Citations

Dec 2, 2010·Investigational New Drugs·Enrique M Ocio, Jesús F San Miguel
Oct 3, 2009·Leukemia·R FonsecaUNKNOWN International Myeloma Working Group
Mar 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikhil C Munshi, Hervé Avet-Loiseau
Jul 30, 2009·Blood·Jean-Luc HarousseauHerve Avet-Loiseau
Apr 13, 2012·Blood·Yiming ZhouJohn D Shaughnessy
Apr 9, 2010·Journal of Hematology & Oncology·Johann MicallefHong Chang
Mar 28, 2013·Journal of Hematology & Oncology·Manujendra N SahaHong Chang
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauStéphane Minvielle
May 17, 2007·Srpski arhiv za celokupno lekarstvo·Olivera MarkovićMilica Colović
Jun 21, 2011·Haematologica·Damien Roos-WeilUNKNOWN Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
May 9, 2014·Epigenomics·Charlotte PawlynGareth J Morgan
Jul 17, 2014·BioMed Research International·P J Teoh, W J Chng
Aug 16, 2014·Blood Cancer Journal·J LuUNKNOWN Chinese Medical Doctor Association Hematology Branch
Feb 18, 2016·Current Hematologic Malignancy Reports·Melissa Gaik-Ming OoiWee Joo Chng
Aug 10, 2011·Leukemia & Lymphoma·Allan JiangHong Chang
Jun 7, 2006·Leukemia & Lymphoma·Evangelos TerposMeletios-Athanassios Dimopoulos
Jul 11, 2007·Expert Review of Molecular Diagnostics·A Keith Stewart, Rafael Fonseca
Dec 12, 2012·Expert Review of Hematology·Kevin D BoydFaith E Davies
Feb 4, 2014·Expert Review of Hematology·Rafael FonsecaMeletios A Dimopoulos
Oct 19, 2013·Seminars in Oncology·Rafael Fonseca, Jorge Monge
Mar 18, 2015·European Journal of Haematology·Hareth NahiNiels Abildgaard
Jul 16, 2011·American Journal of Clinical Pathology·Robert B LorsbachFalko Fend
Nov 29, 2011·Clinics in Laboratory Medicine·Marilyn L Slovak
Oct 11, 2011·Leukemia Research·Nan JiangHong Chang
Jul 7, 2009·Hematology/oncology Clinics of North America·Pei Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.